Bevacizumab-话题@MedSci - 梅斯（MedSci）

#Bevacizumab#

10篇内容 | 1129人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1598477, encodeId=801a15984e783, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, objectType=article, longId=221201, objectId=587522120103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=587522120103, replyNumber=0, likeNumber=64, createdTime=2021-11-30, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=587522120103, moduleTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=587522120103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598476, encodeId=b49915984e6aa, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, objectType=article, longId=214989, objectId=b1e72149892f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e72149892f, replyNumber=0, likeNumber=64, createdTime=2021-07-30, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e72149892f, moduleTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b1e72149892f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598475, encodeId=8e5415984e5b9, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性 , objectType=article, longId=208763, objectId=25ad208e63d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ad208e63d1, replyNumber=0, likeNumber=73, createdTime=2021-03-22, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ad208e63d1, moduleTitle=Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=25ad208e63d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598474, encodeId=549615984e43c, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, objectType=article, longId=197253, objectId=32b119e253bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b119e253bc, replyNumber=0, likeNumber=53, createdTime=2020-07-10, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b119e253bc, moduleTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=32b119e253bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598473, encodeId=4e2c15984e3db, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, objectType=article, longId=189176, objectId=3c381891e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c381891e64b, replyNumber=0, likeNumber=57, createdTime=2020-03-04, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c381891e64b, moduleTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3c381891e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598472, encodeId=772f15984e27e, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=J Clin Oncol：Atezolizumab和Bevacizumab治疗转移肾细胞肿瘤多中心二期研究结果分析, objectType=article, longId=184405, objectId=55ff18440540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55ff18440540, replyNumber=0, likeNumber=56, createdTime=2019-12-09, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55ff18440540, moduleTitle=J Clin Oncol：Atezolizumab和Bevacizumab治疗转移肾细胞肿瘤多中心二期研究结果分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=55ff18440540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598471, encodeId=b2ed15984e1a0, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=Adv Ther：年龄相关的黄斑变性治疗药物转变-Bevacizumab或Ranibizumab转换为Aflibercept, objectType=article, longId=166454, objectId=6ee2166454fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ee2166454fd, replyNumber=0, likeNumber=98, createdTime=2019-05-22, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ee2166454fd, moduleTitle=Adv Ther：年龄相关的黄斑变性治疗药物转变-Bevacizumab或Ranibizumab转换为Aflibercept, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6ee2166454fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598470, encodeId=11b715984e0e9, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=Lancet：Atezolizumab联合Bevacizumab一线治疗晚期肾癌, objectType=article, longId=165880, objectId=aef5165880f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aef5165880f7, replyNumber=0, likeNumber=70, createdTime=2019-05-13, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aef5165880f7, moduleTitle=Lancet：Atezolizumab联合Bevacizumab一线治疗晚期肾癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aef5165880f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598469, encodeId=7ba1159846925, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=CLIN CANCER RES：Plerixafor联合Bevacizumab治疗复发性高级别胶质瘤, objectType=article, longId=151583, objectId=b06a151583fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b06a151583fa, replyNumber=0, likeNumber=69, createdTime=2018-10-24, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b06a151583fa, moduleTitle=CLIN CANCER RES：Plerixafor联合Bevacizumab治疗复发性高级别胶质瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b06a151583fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598468, encodeId=fd8615984682e, content=<a href='/topic/show?id=b122336400' target=_blank style='color:#2F92EE;'>#Bevacizumab#</a>, objectTitle=JAMA:一线化疗联合Cetuximab 或 Bevacizumab对KRAS野生型晚期或转移性结肠直肠癌患者生存的影响, objectType=article, longId=102999, objectId=5d36102999e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d36102999e4, replyNumber=0, likeNumber=65, createdTime=2017-06-24, rootId=0, userName=changhe719, userId=078118606336, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d36102999e4, moduleTitle=JAMA:一线化疗联合Cetuximab 或 Bevacizumab对KRAS野生型晚期或转移性结肠直肠癌患者生存的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5d36102999e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Bevacizumab

2020-05-29

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比

2021-11-30

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效

2021-07-30

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性

2021-03-22

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究

2020-07-10

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验

2020-03-04

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

J Clin Oncol：Atezolizumab和Bevacizumab治疗转移肾细胞肿瘤多中心二期研究结果分析

2019-12-09

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

Adv Ther：年龄相关的黄斑变性治疗药物转变-Bevacizumab或Ranibizumab转换为Aflibercept

2019-05-22

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

Lancet：Atezolizumab联合Bevacizumab一线治疗晚期肾癌

2019-05-13

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

CLIN CANCER RES：Plerixafor联合Bevacizumab治疗复发性高级别胶质瘤

2018-10-24

changhe719 (审核中...)

前往app查看评论内容

#Bevacizumab#

JAMA:一线化疗联合Cetuximab 或 Bevacizumab对KRAS野生型晚期或转移性结肠直肠癌患者生存的影响

2017-06-24

科室
- - 订阅+
  - 更多科室
工具
服务